Replies to post #653272 on NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

pgsd, there was so much misleading information about the DCVax trial because the authors referenced the outdated “First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma” from the Journal of Translational Medicine in 2018. See the footnote:
80.Liau   LM, Ashkan   K, Tran   DD, et al. . First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16(1):142. https://doi.org/10.1186/s12967-018-1507-6

This deception was likely intentional because when you look at the history of this article, it shows:

Article history
Received: 24 August 2023
Accepted: 15 November 2023
Published: 04 December 2023

It seems extremely difficult to believe that the authors did not know about the final results of the trial published in JAMA Oncology in November 2022, which would make the deception particularly egregious in my opinion.

[sentiment_stocks]

Maccari et al. also state that DCVax-L is “administered intradermally every 2 weeks for 3 doses, then every 2 months for 6 doses, and then every 3 months until the vaccine is exhausted” (page 2). This is partially correct, but they omit the fact that DCVax-L is also given intradermally at the time of surgery, before the start of standard of care (SOC) treatment with radiotherapy and temozolomide1.

I believe Ms. AI has that part incorrect as in the P3 trial, the vaccine was not given at the time of surgery, nor before SOC treatment begins.

No big, but that’s an error on the part of the AI.